The Uromigos

Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer 21.03.2022 34:00 ↓

David McDermott attempts to get his point across...again. 

Episode 162: Debate - Adjuvant nivolumab for bladder cancer 14.03.2022 20:07 ↓

Matt Galski and Tom Powles take the FDA and EMA approach respectively. 

Episode 161: Platinum eligibility in urothelial cancer 07.03.2022 23:44 ↓

Shilpa Gupta describes cisplatin and platinum eligibility. 

Episode 160: APCCC - PMSA PET as a diagnostic 28.02.2022 30:18 ↓

Stefano Fanti describes this topic. 

Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer 19.02.2022 21:08 ↓

Axel Bex discusses these topics. 

Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer 19.02.2022 25:56 ↓

Fred Saad describes the results of this trial. 

Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer 18.02.2022 20:49 ↓

Jonathan Rosenberg describes the results of this positive randomised trial.

Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer 18.02.2022 17:16 ↓

Petros Grivas describes the results of this phase 2 trial. 

Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC 17.02.2022 30:32 ↓

Kim Chi describes the results of this randomised phase 3 study. 

Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer 17.02.2022 17:44 ↓

Matthew Smith describes the results of this phase 3 trial. 

Episode 153: Overview of PARP inhibition in prostate cancer 10.02.2022 30:34 ↓

Pete Nelson describes mechanism of action and current clinical application in prostate cancer

Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging 07.02.2022 21:45 ↓

Elizabeth de Vries describes her paper in Annals of Oncology. 

Episode 151: Bladder Cancer ESMO Guidelines update 31.01.2022 27:29 ↓

Joaquim Bellmunt gives an overview of the changes. 

Episode 150: Comparing the quality of life data in renal trials 24.01.2022 31:07 ↓

David Cella unpicks the data across these studies and makes some conclusions. 

Episode 149: Treatment-free survival for ipilimumab and nivolumab 28.12.2021 30:07 ↓

David McDermott describes his Clinical Cancer Research paper on this topic. 

Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer 21.12.2021 27:28 ↓

Chad Tang discusses his recent Lancet oncology paper. 

Episode 147: Renal Cancer Christmas Special 17.12.2021 31:35 ↓

Toni Choueiri looks back at the year in kidney cancer. 

Episode 146: Bladder Cancer Christmas Special 13.12.2021 24:54 ↓

Jonathan Rosenberg discusses 2021 and what to look out for in 2022.

Episode 145: Prostate Cancer Christmas Special 06.12.2021 31:12 ↓

Silke Gillessen and Chris Sweeney give a year in review. 

Episode 144: Pembrolizumab for bladder cancer 02.12.2021 27:39 ↓

Arjun Balar discusses bladder cancer and his recent move to industry. 

Episode 143: The Uromigos Paper of the Month - Determinants of anti- PD-1 response and resistance in clear cell renal cell carcinoma 17.11.2021 28:10 ↓

Samra Turajlic describes her cancer cell paper. 

Episode 141: Movember - Past, Present and Future 05.11.2021 22:21 ↓

Sam Gledhill describes the charity and its work. 

Episode 140: What is the role of ipilimumab in renal cancer? 29.10.2021 25:18 ↓

Mike Atkins discusses the role of CTLA4 inhibition in RCC.

Episode 139: The Uromigos Paper of the Month - Talazoparib in biomarker positive prostate cancer 27.10.2021 23:20 ↓

Tanya Dorff discusses this paper and the role of PARP inhibitors in prostate cancer. 

Episode 138: Renal Cancer ESMO Guidelines Update 22.10.2021 29:12 ↓

Laurence Albiges gives an overview of the new ESMO RCC guidelines and Brian challenges her and Tom.